CU20170029A7 - Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios - Google Patents
Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediariosInfo
- Publication number
- CU20170029A7 CU20170029A7 CUP2017000029A CU20170029A CU20170029A7 CU 20170029 A7 CU20170029 A7 CU 20170029A7 CU P2017000029 A CUP2017000029 A CU P2017000029A CU 20170029 A CU20170029 A CU 20170029A CU 20170029 A7 CU20170029 A7 CU 20170029A7
- Authority
- CU
- Cuba
- Prior art keywords
- composition
- preparation
- disorder
- induction
- useful
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000030833 cell death Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 title 1
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 abstract 1
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>Se describen compuestos de fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular tal como un tumor hematológico, un tumor sólido y/o metástasis de los mismos. Tambien se describe un procedimiento para la preparación de estos compuestos, y los compuestos intermedios que se utilizan en dicho procedimiento de preparación. Los nuevos compuestos de la invención presentan propiedades farmacológicas mejoradas, en particular una potencia mejorada de la inhibición del objetivo Bub1, una inhibición más potente de la proliferación y/o interacciones fármaco reducidas cuando se utilizan en combinación con otros fármacos.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185604 | 2014-09-19 | ||
| EP15176903 | 2015-07-15 | ||
| PCT/EP2015/071340 WO2016042084A1 (en) | 2014-09-19 | 2015-09-17 | Benzyl substituted indazoles as bub1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20170029A7 true CU20170029A7 (es) | 2017-08-08 |
Family
ID=54140475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2017000029A CU20170029A7 (es) | 2014-09-19 | 2015-09-17 | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10350206B2 (es) |
| EP (1) | EP3194379A1 (es) |
| JP (1) | JP6664385B2 (es) |
| KR (1) | KR20170049604A (es) |
| CN (1) | CN107001331A (es) |
| AP (1) | AP2017009803A0 (es) |
| AU (1) | AU2015316796A1 (es) |
| BR (1) | BR112017005444A2 (es) |
| CA (1) | CA2961589A1 (es) |
| CL (1) | CL2017000654A1 (es) |
| CO (1) | CO2017002532A2 (es) |
| CR (1) | CR20170100A (es) |
| CU (1) | CU20170029A7 (es) |
| DO (1) | DOP2017000078A (es) |
| EA (1) | EA032401B1 (es) |
| EC (1) | ECSP17016797A (es) |
| IL (1) | IL251071A0 (es) |
| MA (1) | MA39484A (es) |
| MX (1) | MX2017003664A (es) |
| NI (1) | NI201700034A (es) |
| PE (1) | PE20170697A1 (es) |
| PH (1) | PH12017500509A1 (es) |
| SG (1) | SG11201702082VA (es) |
| TN (1) | TN2017000092A1 (es) |
| TW (1) | TW201615636A (es) |
| UY (1) | UY36311A (es) |
| WO (1) | WO2016042084A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| US9682974B2 (en) | 2013-10-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| PL3102568T3 (pl) | 2014-02-06 | 2019-01-31 | Heptares Therapeutics Limited | Bicykliczne związki aza w postaci agonistów receptorów muskarynowych m1 |
| US10428044B2 (en) | 2014-06-17 | 2019-10-01 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones |
| CR20170100A (es) | 2014-09-19 | 2017-04-24 | Bayer Pharma Aktiengesellchaft | Indazoles sustituidos con bencilo como inhibidores bub1 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| ES2924359T3 (es) | 2017-04-11 | 2022-10-06 | Sunshine Lake Pharma Co Ltd | Compuestos de indazol sustituidos con flúor y usos de los mismos |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5470862A (en) | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| ID22176A (id) | 1996-10-14 | 1999-09-09 | Bayer Ag | Turunan pirazola tersubstitusi-heterosiklilmetil yang baru |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| BR0314196A (pt) | 2002-09-10 | 2005-07-26 | Scios Inc | Inibidores de tgf-beta |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| WO2007038613A2 (en) | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| CA2553513A1 (en) | 2004-01-22 | 2005-08-04 | Altana Pharma Ag | N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| AU2008253311A1 (en) | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellshaft | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| US8354399B2 (en) | 2008-12-18 | 2013-01-15 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| HUE026778T2 (en) | 2009-11-27 | 2016-08-29 | Adverio Pharma Gmbh | Method for producing methyl- {4,6-diamino-2-[1-(2-fluorobenzyl) -1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-5-yl}-methyl carbamate and its purification for its use as a pharmaceutical agent |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| EA026692B1 (ru) | 2010-06-30 | 2017-05-31 | Айронвуд Фармасьютикелз, Инк. | Стимуляторы sgc |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| WO2013167698A1 (en) | 2012-05-11 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| US20160046604A1 (en) | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976334A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| CA2907592A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105452242A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CA2916097A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| JP2016522231A (ja) | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| US9682974B2 (en) | 2013-10-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| SG11201701915TA (en) | 2014-09-19 | 2017-04-27 | Glaxosmithkline Ip Dev Ltd | Novel soluble guanylate cyclase activators and their use |
| JP2017535514A (ja) | 2014-09-19 | 2017-11-30 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 |
| US20170275270A1 (en) | 2014-09-19 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles |
| JP2017534576A (ja) | 2014-09-19 | 2017-11-24 | ネステク ソシエテ アノニム | コンパニオンアニマルにおけるα−アミラーゼ阻害物質でのがんの治療 |
| LT3194376T (lt) | 2014-09-19 | 2019-02-25 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai |
| WO2016042081A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| CR20170100A (es) | 2014-09-19 | 2017-04-24 | Bayer Pharma Aktiengesellchaft | Indazoles sustituidos con bencilo como inhibidores bub1 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
-
2015
- 2015-09-17 CR CR20170100A patent/CR20170100A/es unknown
- 2015-09-17 US US15/512,494 patent/US10350206B2/en not_active Expired - Fee Related
- 2015-09-17 MX MX2017003664A patent/MX2017003664A/es unknown
- 2015-09-17 MA MA039484A patent/MA39484A/fr unknown
- 2015-09-17 TN TN2017000092A patent/TN2017000092A1/en unknown
- 2015-09-17 PE PE2017000480A patent/PE20170697A1/es unknown
- 2015-09-17 EP EP15763619.2A patent/EP3194379A1/en not_active Withdrawn
- 2015-09-17 KR KR1020177010425A patent/KR20170049604A/ko not_active Withdrawn
- 2015-09-17 CU CUP2017000029A patent/CU20170029A7/es unknown
- 2015-09-17 JP JP2017514825A patent/JP6664385B2/ja not_active Expired - Fee Related
- 2015-09-17 AU AU2015316796A patent/AU2015316796A1/en not_active Abandoned
- 2015-09-17 CA CA2961589A patent/CA2961589A1/en not_active Abandoned
- 2015-09-17 BR BR112017005444A patent/BR112017005444A2/pt not_active IP Right Cessation
- 2015-09-17 CN CN201580062951.4A patent/CN107001331A/zh active Pending
- 2015-09-17 SG SG11201702082VA patent/SG11201702082VA/en unknown
- 2015-09-17 EA EA201790649A patent/EA032401B1/ru not_active IP Right Cessation
- 2015-09-17 AP AP2017009803A patent/AP2017009803A0/en unknown
- 2015-09-17 WO PCT/EP2015/071340 patent/WO2016042084A1/en not_active Ceased
- 2015-09-18 UY UY0001036311A patent/UY36311A/es not_active Application Discontinuation
- 2015-09-18 TW TW104131025A patent/TW201615636A/zh unknown
-
2017
- 2017-03-09 IL IL251071A patent/IL251071A0/en unknown
- 2017-03-16 PH PH12017500509A patent/PH12017500509A1/en unknown
- 2017-03-17 CL CL2017000654A patent/CL2017000654A1/es unknown
- 2017-03-17 NI NI201700034A patent/NI201700034A/es unknown
- 2017-03-17 DO DO2017000078A patent/DOP2017000078A/es unknown
- 2017-03-17 CO CONC2017/0002532A patent/CO2017002532A2/es unknown
- 2017-03-17 EC ECIEPI201716797A patent/ECSP17016797A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017000654A1 (es) | 2017-12-11 |
| AU2015316796A1 (en) | 2017-03-30 |
| SG11201702082VA (en) | 2017-04-27 |
| PH12017500509A1 (en) | 2017-08-30 |
| CN107001331A (zh) | 2017-08-01 |
| AP2017009803A0 (en) | 2017-03-31 |
| CO2017002532A2 (es) | 2017-07-11 |
| EP3194379A1 (en) | 2017-07-26 |
| PE20170697A1 (es) | 2017-06-24 |
| NI201700034A (es) | 2017-06-16 |
| CA2961589A1 (en) | 2016-03-24 |
| EA201790649A1 (ru) | 2017-09-29 |
| WO2016042084A1 (en) | 2016-03-24 |
| TN2017000092A1 (en) | 2018-07-04 |
| KR20170049604A (ko) | 2017-05-10 |
| UY36311A (es) | 2016-04-29 |
| US20170273980A1 (en) | 2017-09-28 |
| EA032401B1 (ru) | 2019-05-31 |
| ECSP17016797A (es) | 2017-05-31 |
| CR20170100A (es) | 2017-04-24 |
| BR112017005444A2 (pt) | 2018-04-24 |
| JP6664385B2 (ja) | 2020-03-13 |
| IL251071A0 (en) | 2017-04-30 |
| JP2017530962A (ja) | 2017-10-19 |
| MA39484A (fr) | 2016-03-24 |
| TW201615636A (zh) | 2016-05-01 |
| DOP2017000078A (es) | 2017-06-30 |
| MX2017003664A (es) | 2017-07-13 |
| US10350206B2 (en) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170029A7 (es) | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX380829B (es) | Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa. | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX384884B (es) | Inhibidores de ret. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| EA032953B1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX380940B (es) | Compuestos de pirazol y metodo para elaborar y usar los compuestos. | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MY176235A (en) | Compounds that inhibit mcl-1 protein | |
| NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
| MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| MX376824B (es) | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). | |
| CO2018007221A2 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
| CL2013002446A1 (es) | Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer. | |
| MX388752B (es) | Composiciones novedosas, usos y métodos para hacerlas. |